

# 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virologic response to etravirine

Pedro Cahn,<sup>1</sup> Jean-Michel Molina,<sup>2</sup> William Towner,<sup>3</sup> Monika Peeters,<sup>4</sup> Johan Vingerhoets,<sup>4</sup> Greet Beets,<sup>4</sup> Benny Baeten,<sup>4</sup> **Goedele De Smedt**<sup>®</sup>

Pedro Cahn, MD Fundación Huésped Angel Peluffo 3932 **Buenos Aires** Argentina, C1202ABB pcahn@huesped.org.ar

<sup>1</sup>Fundación Huésped, Buenos Aires, Argentina; <sup>2</sup>Assistance Publique Hôpitaux de Paris and University of Paris, Paris, France; <sup>3</sup>Kaiser Permanente, Los Angeles, CA, USA; <sup>4</sup>Tibotec BVBA, Mechelen, Belgium

# Abstract

### Background

Pooled 48-week analysis from the ongoing, randomized, double-blind, placebo-controlled DUET-1 and DUET-2 Phase III trials demonstrated the efficacy and safety of etravirine (ETR; TMC125) in treatment-experienced patients.

#### Methods

Treatment-experienced patients with documented NNRTI resistance, ≥3 primary protease inhibitor (PI) mutations and viral load >5000 copies/mL were randomized 1:1 to receive ETR 200mg or placebo bid plus background regimen (BR; darunavir with low-dose ritonavir [DRV/r], optimized NRTI[s] ± enfuvirtide [ENF]). The primary endpoint was the percentage of patients with confirmed viral load <50 copies/mL (intent-to-treat [ITT] population; time-to-loss of virologic response [TLOVR] algorithm). Subgroup analyses essed the effect of baseline characteristics on response to ETR.

### Results


One thousand, two hundred and three patients were included in the pooled analysis: 599 and 604 patients in the ETR and placebo groups, respectively. Baseline characteristics and demographics were comparable between treatment groups: male (90% vs 89%), median age (46 vs 45 years), Caucasian (70% vs 70%), viral load (both 4.8 log<sub>10</sub> c/mL). CD4 cell count (99 cells/mm<sup>3</sup> vs 109 cells/mm<sup>3</sup>), hepatitis B and/or C coinfection (13% vs 12%), and previous NNRTI use (92% vs 92%). The impact of baseline characteristics on virologic response is shown below


	Responders (<50 copies/mL at Week 48), % (patient numbers)			
	ETR + BR (n=599)	Placebo + BR (n=604)	Difference vs placebo group	p value
Effect by patient demog	graphics			
Race				
Black	53 (37/70)	34 (24/70)	19	0.0150
Caucasian	61 (228/373)	41 (156/376)	20	< 0.0001
Hispanic	57 (34/60)	36 (24/66)	20	0.0118
Effect of disease chara	cteristics			
*Viral load				
<30 000c/mL	76 (125/165)	56 (97/174)	20	< 0.0001
30 000–100 000c/mL	61 (126/206)	39 (82/213)	23	< 0.0001
>100 000c/mL	49 (112/228)	28 (61/217)	21	< 0.0001
*CD4 cell count				
<50 cells/mm³	45 (96/213)	22 (45/209)	24	< 0.0001
50–200 cells/mm <sup>3</sup>	65 (136/208)	48 (99/208)	18	0.0002
200–350 cells/mm <sup>3</sup>	74 (88/119)	52 (65/125)	22	0.0001
≥350 cells/mm³	72 (42/58)	51 (31/61)	22	0.0061
Hepatitis B and/or C coint	ection			
Negative	61 (304/495)	38 (190/495)	23	< 0.0001
Positive	60 (43/72)	51 (34/67)	9	0.3028
*Effect of ENF use				
ENF not used	59 (192/327)	36 (117/322)	22	< 0.0001
ENF reused	52 (62/119)	24 (30/123)	28	< 0.0001
ENF used de novo	71 (109/153)	58 (93/159)	13	0.0116


The proportion of responders was also greater in the ETR versus placebo group when analyzed by gender, age, region, or previous NNRTI use.

#### Conclusions

At Week 48, consistently more patients in the ETR group achieved undetectable viral load <50 copies/mL than in the placebo group, irrespective of baseline characteristics. Baseline viral load, CD4 cell count and ENF were significant predictors of response in both treatment groups








## Conclusions

- ETR + BR demonstrated superior virologic responses than placebo + BR in treatment-experienced patients at 48 weeks
- 61% of patients in the ETR group achieved confirmed undetectable viral load (<50 copies/mL) compared with 40% in the placebo group.
- When analyzed by selected baseline characteristics, patients in the ETR group consistently achieved higher response rates than those in the placebo group, irrespective of ENF use, race, disease characteristics, or previous NNRTI use.
- Baseline viral load, CD4 cell count, ENF use and number of sensitive background ARVs were predictors of response in both treatment groups; nevertheless ETR provided added benefit in each subgroup.

### Acknowledgments

Ne express our gratitude to the patients who participated in the studies, as well as the study center



staff, the data safety and monitoring board, clinical event adjudication panels, Virco, Tibotec personnel and the following principal invest

#### DUET-1

Argentina: HA Ariza, J Benetucci, LM Calanni, LI Cassetti, J Corral, DO David, A Krolewiecki, MH Losso, P Patterson, RA Teijeiro; Brazil: CA da Cunha, B Grinsztejn, EG Kallas, JV Madruga, EM Netto, JH Piloto, M Schechter, J Suleiman, A Timerman; Chile: J Ballesteros, R Northland; Costa Rica: AA Alvilés Montoya, G Herrera Martinez, A Solano Chinchilla; France: M Dupon, C Katlama, JM Livrozet, P Morlat, G Pialoux, C Piketty, I Poizot-Martin; Mexico: J Andrade-Villanueva, G Reyes-Terán, J Sierra-Madero; **Panama**: A Canton, A Rodriguez, N Sosa; **Puerto Ricc**: JO Morales Ramirez, JL Santana Bagur, R Soto-Malave; **Thailand**: T Anekthananon, P Mootsikapun, K Ruxrungtham; **USA**: M Albrecht, N Bellos, R Bolan, P Brachman, C Brinson, F Cruickshank, R Elion, WJ Fessel, R Haubrich, T Hawkins, S Hodder, P Hutcherson, T Jefferson, H Katner, C Kinder, M Kozal, J Lalezari, J Leider, D McDonough, A Mills, K Mounzer, J Nadler, D Norris, W O'Brien, G Pierone, K Raben, B Rashbaum, M Rawlings, B Rodwick, P Ruane, J Sampson, S Schrader, A Scribner, M Sension, D Sweet, B Wade, D Wheeler, A Wilkin, T Wilkin, T Wills, M Wohlfeiler, K Workowski

#### DUET-2

DUET-2 Australia: J Chuah, D Cooper, B Eu, J Hoy, C Workman; Belgium: N Clumeck, R Colebunders, M Moutschen; Canada: J Gill, K Gough, P Junod, D Kilby, J Montaner, A Rachlis, B Trottier, CM Tsoukas, S Walmsley; France: C Arvieux, L Cotte, JF Delfraissy, C Katlama, PM Girard, B Marchou, D Vittecoq, Y Yazdanpanah, P Yeni; Germany: K Arasteh, S Esser, G Fätkenheuer, H Gellermann, K Göbels, FD Goebel, H Jäger, JK Rockstroh, D Schuster, S Staszewski, A Stoehr; Italy: A Antinori, G Carosi, G Di Perri, R Esposito, A Lazzarin, F Mazzotta, G Pagano, E Raise, S Rusconi, L Sighinofit, F Suter; The Netherlands: PHJ Frissen, JM Prins, BJA Rijnders; Poland: A Horban; Portugal: F Antunes, M Miranda, J Vera; Spain: P Domingo, B Clotet, G Garcia, JM Gatell, J González-Lahoz, J L ópez-Aldeoure, D Podramczer: UK: P Easterbrook, M Fisher, M Johnson, C Orkin, E Wikins: USA: Vir Miniaruda, J. Vera, Spant: P. Orinnigo, B. Gloter, & Carcia, JM Gateli, J. Gonzalez-Lahog, J. López-Aldeguer, D. Podzamczer; UK: P. Easterbrook, M. Fisher, M. Johnson, C. Orkin, E. Wilkins; USA: B. Barnett, J. Baxter, G. Beatty, D. Berger, C. Borkert, T. Campbell, C. Cohen, M. Conant, J. Ernst, C. Farthing, T. File, M. Frank, JE Gallant, AE Greenberg, C. Hicks, DT Jayaweera, S. Kerkar, N. Markowitz, C. Martorell, C. McDonald, D. McMahon, M. Mogyoros, RA Myers Jr, G. Richmond, K. Sathasivam, S. Schneider, H. Schrager, P. Shalit, FP Siegal, L. Sloan, K. Smith, S. Smith, P. Tebas, LS Tkatch.

Supported by Tibotec

Presented at the XVIIth International AIDS Conference, Mexico City, Mexico, August 3–8 2008.

This poster is available on-line at www.tibotec.com